FEB 02, 2022
Dr. Marjan Farid discusses the ONSET-2 Phase 3 trial results of varenicline nasal spray, an FDA-approved treatment for signs and symptoms of dry eye disease (DED). In the study she presented at AAO 2021, 758 patients with mild, moderate, or severe DED were treated with the nasal spray and surveyed against controls. The treatment stimulates the trigeminal nerve to increase lacrimal flow and addresses the loss of homeostasis. Dr. Farid says she will be looking to use varenicline early in DED symptomology before inflammation has set in.
Relevant financial disclosures: None.